Dublin, April 11, 2022 (GLOBE NEWSWIRE) -- The "Infertility Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global infertility drugs market reached a value of US$ 3.47 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 4.95 Billion by 2027 exhibiting a CAGR of 5.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.
Infertility Drugs Market Trends:
Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs.
Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates.
Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global infertility drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration, distribution channel and end user.
Breakup by Drug Class:
- Gonadotropin
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Others
Breakup by Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by End User:
- Male
- Female
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.
Key Questions Answered in This Report:
- How has the global infertility drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global infertility drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global infertility drugs market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Infertility Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Gonadotropin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Aromatase Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Selective Estrogen Receptor Modulators (SERMs)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Biguanides
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Intravenous
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Subcutaneous
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Intramuscular
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by End User
9.1 Male
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Female
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Region
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbott Laboratories
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 Bayer AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Ferring Pharmaceuticals
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 Livzon Pharmaceutical Group Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 Mankind Pharma
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Merck & Co. Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.10 Sanofi S.A.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Theramex
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/nfg34w
Attachment
